Page last updated: 2024-08-24

telmisartan and Cardiovascular Diseases

telmisartan has been researched along with Cardiovascular Diseases in 138 studies

Research

Studies (138)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	74 (53.62)	29.6817
2010's	60 (43.48)	24.3611
2020's	4 (2.90)	2.80

Authors

Authors	Studies
Baptiste, PJ; Clase, C; Cunnington, M; Leyrat, C; Mann, JFE; Schultze, A; Tomlinson, LA; Wing, K; Wong, AYS	1
Kang, TS; Kim, BK; Kim, JY; Lee, CJ; Lee, SH; Park, S; Sung, JH	1
AlHabib, KF; Altuntas, Y; Anand, SS; Avezum, A; Chifamba, J; Dans, A; Dehghan, M; Diaz, R; Gupta, R; Iqbal, R; Ismail, N; Kaur, M; Khatib, R; Lear, S; Li, N; Liu, X; Lopez-Jaramillo, P; Mente, A; Mohammadifard, N; Mohan, V; Rangarajan, S; Rosengren, A; Seron, P; Sheridan, P; Smuts, M; Soman, B; Swaminathan, S; Szuba, A; Teo, K; Turbide, G; Wielgosz, A; Yusoff, K; Yusuf, R; Yusuf, S; Yusufali, A	1
Basiak, M; Krysiak, R; Okopień, B; Szkróbka, W	1
Böhm, M; Lonn, EM; Mahfoud, F; Mancia, G; Mann, JFE; Redon, J; Schmieder, RE; Schumacher, H; Sliwa, K; Teo, KK; Weber, MA; Williams, B; Yusuf, S	1
Avorn, J; Fralick, M; Kesselheim, AS; Schneeweiss, S	1
Böhm, M; Lonn, E; Mahfoud, F; Mancia, G; Mann, JFE; Redon, J; Schmieder, R; Schumacher, H; Sliwa, K; Teo, KK; Weber, M; Williams, B; Yusuf, S	1
Böhm, M; Lonn, EM; Mahfoud, F; Mancia, G; Mann, JFE; Marx, N; Redon, J; Schmieder, RE; Schumacher, H; Sliwa, K; Teo, KK; Weber, MA; Williams, B; Yusuf, S	1
Kjeldsen, S; Mancia, G; Mattheus, M; Schmieder, R; Unger, T	1
Bentzen, BH; Grunnet, M; Hansen, HH; Hyveled-Nielsen, L; Lassen, JB; Sundgreen, C	1
Böhm, M; Laufs, U; Schmieder, R; Schumacher, H; Sleight, P; Teo, K; Unger, T; Yusuf, S	1
Caffrey, JL; Chang, CH; Lai, MS; Lin, JW; Wu, LC	1
Böhm, M; Foulquier, S; Schmieder, R; Schumacher, H; Sleight, P; Teo, K; Unger, T; Yusuf, S	1
Kaul, U; Mansoor, A; Sabbah, ZA	1
Chalmers, J	2
Anderson, C; Bosch, J; Gao, P; Joseph, PG; Khatib, R; O'Donnell, MJ; Probstfield, JL; Teo, KK; Yusuf, S	1
Basile, JN; Gradman, AH	1
Anderson, C; Böhm, M; Custodis, F; Diener, HC; Fagard, R; Laufs, U; Leong, D; Lonn, E; Mancia, G; O'Donnell, M; Redon, J; Schmieder, R; Schumacher, H; Sleight, P; Sliwa, K; Teo, K; Unger, T; Yusuf, S	1
Anderson, C; Cukierman-Yaffe, T; Gao, P; Gerstein, HC; Teo, K; Yusuf, S	1
Jinnouchi, H; Kataoka, K; Kim-Mitsuyama, S; Matsui, K; Node, K; Ogawa, H; Sekigami, T; Soejima, H; Yamamoto, E; Yamamuro, M; Yasuda, O	1
Currier, JS; Hodis, HN; Kelesidis, T; Lake, JE; Liao, DH; Seang, S; Stein, JH	1
Brunner, HR; Foster, C; Huo, Y; Michel, MC	1
Chen, CH; Cheng, HM; Hoshide, S; Huang, QF; Kario, K; Park, CG; Park, S; Wang, JG	1
Barzilay, J; Clase, CM; Gao, P; Mann, JF; Schmieder, RE; Smyth, A; Teo, KK; Tobe, S; Yusuf, S	1
Weber, MA	3
Krzesinski, JM; Scheen, AJ	1
Dahlöf, B; Ritz, E	2
Kurtz, TW	2
Sharma, AM	2
Galle, J	1
Burnier, M; Hess, O; Lüscher, T; Waeber, B	1
Banas, B; Büchner, N; Krämer, BK	1
Bangalore, S; Messerli, FH; Ram, VS	1
van den Meiracker, AH	1
Cohn, JN	1
Düsing, R; Nitschmann, S	1
Budaj, A; Chaithiraphan, S; Dickstein, K; Dyal, L; Keltai, M; Maggioni, A; Mann, JF; McQueen, M; Metsärinne, K; Oto, A; Parkhomenko, A; Piegas, LS; Pogue, J; Schmieder, RE; Schumacher, H; Svendsen, TL; Teo, KK; Wang, X; Yusuf, S	1
Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; VanderMaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S	1
Harrison, D; Ripley, TL	1
Anderson, C; Copland, I; Dagenais, G; Dyal, L; Pogue, J; Schumacher, H; Sleight, P; Teo, K; Yusuf, S	1
Einecke, D	1
Schindler, C	1
Doumas, M; Papademetriou, V	1
Bressolle, C; Fichet, J	1
Achard, JM; Fournier, A; Fournier, RO	1
Anderson, C; Cukierman-Yaffe, T; Gerstein, HC; Hilbrich, L; Jackson, SH; Sleight, P; Teo, K; Yusuf, S; Zhao, F	1
Chachibaia, ZK; Gerasimenko, ON; Shpagin, IS; Shpagina, LA; Zueva, MA	1
Hedner, T; Kjeldsen, SE; Narkiewicz, K; Oparil, S	1
Heneghan, C; Perera, R; Thompson, M	1
Link, A; Reil, JC; Selejan, S	1
Amsterdam, EA; Liebson, PR	1
Anderson, C; Cowan, BR; Doughty, RN; Jennings, GL; Krittayaphong, R; Lonn, E; Marwick, TH; Reid, CM; Sanderson, JE; Schmieder, RE; Teo, K; Wadham, AK; Worthley, SG; Young, AA; Yu, CM; Yusuf, S	1
Terrosu, P; Verdecchia, P	1
Guthrie, R	1
Elliott, HL	1
Mancia, G; Unger, T; Zanchetti, A	1
Sleight, P	3
Ferrari, R	1
Remuzzi, G; Ruggenenti, P	1
Basile, J	1
Chen, JH; Fagard, R; Gao, P; Jansky, P; Jennings, G; Kim, JH; Liu, L; Mancia, G; Probstfield, J; Schmieder, RE; Sleight, P; Teo, K; Trimarco, B; Verdecchia, P; Yusuf, S	1
Arnheim, K	1
Baumhäkel, M; Böhm, M	1
Neldam, S	1
Oğuz, A	1
Hoogwerf, BJ	1
Baumhäkel, M; Böhm, M; Dagenais, GR; Diaz, R; Gao, P; Jansky, P; Jennings, GL; Liu, L; Mann, JF; Probstfield, J; Sleight, P; Teo, K; Yusuf, S	1
Deng, Q; Liu, L; Liu, M; Ma, L; Wang, W; Zhang, Y	1
Capogrosso, C; Di Michele, S; Galzerano, A; Galzerano, D; Gaudio, C; Lama, D; Paparello, P	1
Benndorf, RA; Böger, RH; Deppe, S; Weiss, J	1
Ahrens, K; Bramlage, P	1
Alonso, I; Ayala, DE; Fernández, JR; Fontao, MJ; Hermida, RC; Mojón, A	1
Ceska, R; Krutská, S; Vrablík, M; Zlatohlávek, L	1
Anderson, C; Arima, H; Binbrek, A; Chazova, I; Commerford, P; Dans, A; Dyal, L; Gao, P; Holwerda, N; Paolasso, E; Pogue, J; Schumacher, H; Teo, K; Unger, T; Young, J; Yusuf, S	1
Baumhäkel, M; Böhm, M; Mahfoud, F; Werner, C	1
Guthrie, RM	1
Chaithiraphan, S; Chen, JH; Dans, AL; Gao, P; Jae-Hyung, K; Lisheng, L; Teo, K; Yusoff, K; Yusuf, S; Zhu, J	1
Bilo, G; Choi, J; Kilama, MO; Mancia, G; Parati, G; Ruilope, LM	1
Frampton, JE	1
Ruilope, LM; Segura, J; Zamorano, JL	1
Barzilay, JI; Commerford, P; Dans, A; Ferreira, R; Gao, P; Keltai, M; Paolasso, E; Probstfield, J; Rydén, L; Schumacher, H; Teo, K; Yusuf, S	1
Hasegawa, H; Kobayashi, Y; Komuro, I; Mizuguchi, T; Namiki, T; Narumi, H; Ohtsuka, M; Takano, H	1
De Caterina, R; Di Iorio, A; Falasca, K; Mancino, P; Ucciferri, C; Vecchiet, J	1
Jennings, G; Liu, GL; Mancia, G; Redon, J; Ryden, L; Schmieder, R; Schumacher, H; Sleight, P; Teo, K; Verdecchia, P; Yusoff, K; Yusuf, S	1
Cao, Z; Cooper, ME	1
Avezum, A; Dans, A; Ferreira, R; Gafni, A; Gao, P; Lamy, A; Teo, K; Tong, W; Wang, X; Young, J; Yusuf, S	1
Goyal, BR; Goyal, RK; Mehta, AA; Parmar, K	1
Derosa, G; Maffioli, P	1
Angeli, F; Gentile, G; Mazzotta, G; Reboldi, G; Verdecchia, P	1
Akhrass, PR; McFarlane, SI	1
Böhm, M; Fagard, R; Gao, P; Mancia, G; Pogue, J; Redon, J; Schumacher, H; Sleight, P; Teo, K; Verdecchia, P; Weber, M; Williams, B; Yusoff, K; Yusuf, S	1
Deng, Q; Liu, L; Liu, M; Ma, L; Sun, H; Wang, J; Wang, W; Zhang, Y; Zhao, Y	1
Goto, SN; Iwata, K; Takagi, H; Umemoto, T; Yamamoto, H	1
Kjeldsen, SE; Okin, PM	1
Binbrek, AS; Chazova, I; Dagenais, G; Dans, AL; Ferreira, R; Gao, P; Healey, J; Holwerda, N; Iacobellis, G; Karatzas, N; Keltai, M; Mancia, G; Sleight, P; Teo, K; Verdecchia, P; Yusuf, S	1
Grassi, B; Neumann, I	1
Dudek, E; Michalak, M; Millott, R	1
Volpe, M	1
Barzilay, JI; Clase, CM; Gao, P; Mann, JF; Mente, A; Sleight, P; Teo, KK; Yusuf, S	1
Avezum, A; Dagenais, G; Dans, T; Dehghan, M; Gao, P; Mente, A; Probstfield, JL; Sleight, P; Teo, KK; Yusuf, S	1
Probstfield, JL	1
Unger, T	1
Weber, M	1
Kurtz, TW; Pershadsingh, HA	1
Anderson, C; Hilbrich, L; Mookadam, F; Pogue, J; Ramos, B; Schumacher, H; Sleight, P; Teo, K; Yusuf, S	1
Takeuchi, M; Yamagishi, S	1
Doggrell, SA	1
Anderson, C	1
Baumhäkel, M; Böhm, M; Koon, T; Probstfield, JL; Schmieder, R; Yusuf, S; Zhao, F	1
Abdullah, MM; Moghadasian, MH; Pierce, GN; Xu, Z	1
Petkow-Dimitrow, P	1
Giles, TD	1
Asmar, R; El Feghali, R; Pannier, B; Smetana, K; Teo, K; Topouchian, J; Wang, S; Zhao, F	1
Fitchett, D	1
Nakamura, K; Yamagishi, S	1
McMurray, JJ	1
Anderson, C; Copland, I; Dagenais, G; Dyal, L; Pogue, J; Schumacher, H; Sleight, P; Teo, KK; Yusuf, S	1
Goyal, BR; Goyal, RK; Mehta, AA; Mesariya, P	1
Heroys, J; Jakobsen, A; Mancia, G; Ralph, A; Rees, T; Shaw, M	1
Inoue, T; Node, K	1
Ramahi, TM	1
Yusuf, S	1

Reviews

43 review(s) available for telmisartan and Cardiovascular Diseases

Article	Year
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet (London, England), 2017, Jun-03, Volume: 389, Issue:10085 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Female; Follow-Up Studies; Hospitalization; Humans; Hypertension; Hypotension; Male; Middle Aged; Multicenter Studies as Topic; Ramipril; Randomized Controlled Trials as Topic; Telmisartan	2017
An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors. Expert review of cardiovascular therapy, 2013, Volume: 11, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; International Cooperation; Practice Guidelines as Topic; Risk Factors; Severity of Illness Index; Telmisartan	2013
Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease. Pharmacology & therapeutics, 2016, Volume: 164 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Antihypertensive Agents; Atherosclerosis; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Culture Techniques; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Gene Knockout Techniques; Glucose; Humans; Hypertension; Kidney; Lipid Metabolism; Metabolic Diseases; Oxadiazoles; Renin-Angiotensin System; Stroke; Telmisartan	2016
Target Blood Pressure in Patients with Diabetes: Asian Perspective. Yonsei medical journal, 2016, Volume: 57, Issue:6 Topics: Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hypotension; Male; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Reference Values; Risk Factors; Stroke; Telmisartan	2016
Beyond the classic angiotensin-receptor-blocker profile. Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5 Suppl 1 Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Humans; Metabolic Syndrome; PPAR gamma; Receptor, Angiotensin, Type 1; Telmisartan	2008
The value of current interventions for obesity. Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5 Suppl 1 Topics: Adipogenesis; Angiotensin II Type 1 Receptor Blockers; Bariatric Surgery; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metabolic Syndrome; Obesity; Risk Factors; Telmisartan; Weight Loss	2008
Reduction of proteinuria with angiotensin receptor blockers. Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5 Suppl 1 Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biomarkers; Cardiovascular Diseases; Diabetic Nephropathies; Drug Therapy, Combination; Enalapril; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan	2008
Recent advances in cardiovascular risk reduction: implications of ONTARGET. Clinical cornerstone, 2009, Volume: 9 Suppl 3 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Risk Reduction Behavior; Telmisartan	2009
Lessons learned from the ONTARGET and TRANSCEND trials. Current atherosclerosis reports, 2009, Volume: 11, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Ramipril; Randomized Controlled Trials as Topic; Telmisartan; Treatment Outcome; United States	2009
Telmisartan prevents cardiovascular events in a broad group of at-risk patients. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:18 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan; Treatment Outcome	2009
Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both? Future cardiology, 2010, Volume: 6, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Humans; Hypertension; Losartan; Ramipril; Risk Factors; Telmisartan; Tetrazoles	2010
[Renin-angiotensin-aldosterone system inhibition and cardiovascular protection]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2009, Volume: 37 Suppl 6 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Ramipril; Renin-Angiotensin System; Telmisartan	2009
Telmisartan in high-risk cardiovascular patients. The American journal of cardiology, 2010, Jan-04, Volume: 105, Issue:1 Suppl Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Humans; Kidney Diseases; Ramipril; Risk Factors; Telmisartan	2010
Renin-angiotensin system blockade and cardiovascular and renal protection. The American journal of cardiology, 2010, Jan-04, Volume: 105, Issue:1 Suppl Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Drug Therapy, Combination; Humans; Kidney Diseases; Ramipril; Telmisartan	2010
New standards in hypertension and cardiovascular risk management: focus on telmisartan. Vascular health and risk management, 2010, Mar-24, Volume: 6 Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Calcium Channel Blockers; Cardiovascular Diseases; Cardiovascular System; Humans; Hypertension; Ramipril; Risk Factors; Telmisartan	2010
Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:7 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Telmisartan	2010
Importance of a fixed combination of telmisartan and amlodipine for the treatment of hypertension. Drugs of today (Barcelona, Spain : 1998), 2010, Volume: 46, Issue:5 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Humans; Hypertension; Risk Factors; Severity of Illness Index; Telmisartan	2010
[Comprehensive management of cardiovascular risk. Focusing on telmisartan]. Vnitrni lekarstvi, 2010, Volume: 56, Issue:8 Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atherosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Risk Factors; Telmisartan	2010
From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors. Cardiology, 2010, Volume: 117, Issue:3 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cardiovascular System; Disease Progression; Humans; Ramipril; Risk Factors; Telmisartan; Treatment Outcome	2010
Telmisartan: a review of its use in cardiovascular disease prevention. Drugs, 2011, Apr-16, Volume: 71, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Drug Interactions; Endothelium, Vascular; Humans; Telmisartan; Treatment Outcome	2011
Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes. Acta diabetologica, 2012, Volume: 49, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypertension; Renin-Angiotensin System; Risk Factors; Telmisartan	2012
Nifedipine and telmisartan for the treatment of hypertension: the TALENT study. Expert review of cardiovascular therapy, 2011, Volume: 9, Issue:12 Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Calcium Channel Blockers; Cardiovascular Diseases; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Hypertension; Nifedipine; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan	2011
Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert review of clinical pharmacology, 2011, Volume: 4, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Morbidity; Randomized Controlled Trials as Topic; Telmisartan	2011
Telmisartan and cardioprotection. Vascular health and risk management, 2011, Volume: 7 Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Cardiotonic Agents; Cardiovascular Diseases; Diabetes Mellitus; Humans; Hypertension; Risk; Telmisartan	2011
Effects of telmisartan on C-reactive protein levels: a meta-analysis of randomized controlled trials. International journal of cardiology, 2012, Apr-19, Volume: 156, Issue:2 Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Humans; Randomized Controlled Trials as Topic; Telmisartan; Treatment Outcome	2012
The endoplasmic reticulum in cardiovascular health and disease. Canadian journal of physiology and pharmacology, 2012, Volume: 90, Issue:9 Topics: Animals; Apoptosis; Autophagy; Benzimidazoles; Benzoates; Cardiovascular Diseases; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Heart; Humans; Organogenesis; Solanaceous Alkaloids; Telmisartan; Treatment Outcome; Unfolded Protein Response	2012
Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan. Expert review of cardiovascular therapy, 2012, Volume: 10, Issue:8 Topics: Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypertension; Telmisartan; Tetrazoles; Valine; Valsartan	2012
Telmisartan. BIBR 277, Micardis, Pritor. Drugs in R&D, 2002, Volume: 3, Issue:4 Topics: Animals; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hypertension; Telmisartan	2002
How cost-effective are new preventive strategies for cardiovascular disease? The American journal of cardiology, 2003, May-22, Volume: 91, Issue:10A Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Life Expectancy; Models, Econometric; Ramipril; Survival Analysis; Telmisartan; United States	2003
The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. The American journal of cardiology, 2003, May-22, Volume: 91, Issue:10A Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Ramipril; Renin-Angiotensin System; Telmisartan	2003
The telmisartan programme of research tO show Telmisartan End-organ proteCTION (PROTECTION) programme. Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2003, Volume: 21, Issue:6 Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hypertension; Kidney Diseases; Telmisartan	2003
Editorial overview: The 'sartans': is it premature to consider PPARgamma receptor agonism a bonus? Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:3 Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypertension; Irbesartan; Losartan; PPAR gamma; Rats; Rats, Zucker; Telmisartan; Tetrazoles	2005
Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta diabetologica, 2005, Volume: 42 Suppl 1 Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypertension; Metabolic Syndrome; PPAR gamma; Telmisartan	2005
The obese patient with diabetes mellitus: from research targets to treatment options. The American journal of medicine, 2006, Volume: 119, Issue:5 Suppl 1 Topics: Adipogenesis; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Obesity; Renin-Angiotensin System; Telmisartan; Weight Loss	2006
Hypertension treatment and implications of recent cardiovascular outcome trials. Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2006, Volume: 24, Issue:2 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Enalapril; Humans; Hypertension; Randomized Controlled Trials as Topic; Telmisartan	2006
[New therapeutic targets for ACE inhibitors and angiotensin receptor blockers]. Polskie Archiwum Medycyny Wewnetrznej, 2007, Volume: 117, Issue:4 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypertension; Losartan; Metabolic Syndrome; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Risk Reduction Behavior; Telmisartan; Treatment Outcome	2007
A perspective on telmisartan and cardiovascular risk. Reviews in cardiovascular medicine, 2007,Summer, Volume: 8, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Half-Life; Humans; Peripheral Vascular Diseases; Phenotype; Risk Assessment; Risk Factors; Stroke Volume; Telmisartan	2007
Clinical trial update: focus on the ONTARGET study. Vascular health and risk management, 2007, Volume: 3, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Randomized Controlled Trials as Topic; Telmisartan	2007
Telmisartan, its potential therapeutic implications in cardiometabolic disorders. Recent patents on cardiovascular drug discovery, 2006, Volume: 1, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetic Retinopathy; Humans; Insulin Resistance; PPAR gamma; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Renin-Angiotensin System; Telmisartan	2006
Cardiac and vascular protection: the potential of ONTARGET. Medscape journal of medicine, 2008, Mar-26, Volume: 10 Suppl Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiotonic Agents; Cardiovascular Diseases; Clinical Trials as Topic; Drug Delivery Systems; Drug Therapy, Combination; Humans; Ramipril; Telmisartan; Treatment Outcome	2008
Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications. Postgraduate medicine, 2001, Volume: 109, Issue:4 Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biological Availability; Biphenyl Compounds; Cardiovascular Diseases; Humans; Imidazoles; Irbesartan; Kidney Diseases; Losartan; Metabolic Clearance Rate; Patient Selection; Renin-Angiotensin System; Telmisartan; Tetrazoles; Thiophenes; Treatment Outcome; Valine; Valsartan	2001
Angiotensin II and trials of cardiovascular outcomes. The American journal of cardiology, 2002, Jan-24, Volume: 89, Issue:2A Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Clinical Trials as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Ramipril; Survival Rate; Telmisartan; Treatment Outcome	2002
From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. The American journal of cardiology, 2002, Jan-24, Volume: 89, Issue:2A Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Carotid Artery Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prognosis; Ramipril; Receptor, Angiotensin, Type 1; Telmisartan; Treatment Outcome; Ultrasonography; Ventricular Dysfunction, Left	2002

Trials

38 trial(s) available for telmisartan and Cardiovascular Diseases

Article	Year
Effects of high-intensity statin combined with telmisartan versus amlodipine on glucose metabolism in hypertensive atherosclerotic cardiovascular disease patients with impaired fasting glucose: A randomized multicenter trial. Medicine, 2022, Sep-09, Volume: 101, Issue:36 Topics: Amlodipine; Atherosclerosis; Cardiovascular Diseases; Fasting; Glucose; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insulin Resistance; Prediabetic State; Rosuvastatin Calcium; Telmisartan	2022
Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries. The American journal of clinical nutrition, 2020, 04-01, Volume: 111, Issue:4 Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Eggs; Female; Humans; Lipids; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Ramipril; Telmisartan	2020
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. European heart journal, 2018, 09-01, Volume: 39, Issue:33 Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Ramipril; Risk Assessment; Single-Blind Method; Stroke; Telmisartan; Treatment Outcome	2018
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. European heart journal, 2019, 07-01, Volume: 40, Issue:25 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Case-Control Studies; Diabetes Mellitus; Diastole; Drug Therapy, Combination; Heart Failure; Hospitalization; Humans; Hypertension; Myocardial Infarction; Peripheral Arterial Disease; Ramipril; Retrospective Studies; Risk Factors; Stroke; Systole; Telmisartan	2019
Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. American heart journal, 2013, Volume: 166, Issue:2 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Ramipril; Risk; Telmisartan	2013
Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis. Journal of hypertension, 2014, Volume: 32, Issue:6 Topics: Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cardiovascular System; Coronary Artery Disease; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Myocardial Infarction; Peripheral Vascular Diseases; Stroke; Telmisartan; Treatment Outcome	2014
The mini-mental state examination, clinical factors, and motor vehicle crash risk. Journal of the American Geriatrics Society, 2014, Volume: 62, Issue:8 Topics: Accidents, Traffic; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Automobile Driving; Benzimidazoles; Benzoates; Cardiovascular Diseases; Dementia; Diabetes Complications; Female; Humans; Male; Neuropsychological Tests; Predictive Value of Tests; Prospective Studies; Ramipril; Risk; Telmisartan	2014
Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies. The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:7 Topics: Aged; Aged, 80 and over; Aging; Benzimidazoles; Benzoates; Cardiovascular Diseases; Chronic Disease; Cognition Disorders; Dementia; Disabled Persons; Female; Glucose Metabolism Disorders; Humans; Male; Middle Aged; Ramipril; Risk Factors; Telmisartan	2015
A trial of telmisartan prevention of cardiovascular diseases (ATTEMPT-CVD): Biomarker study. European journal of preventive cardiology, 2016, Volume: 23, Issue:9 Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biomarkers; Blood Pressure; Cardiovascular Diseases; Creatinine; Female; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Risk Factors; Telmisartan; Time Factors; Treatment Outcome	2016
Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney international, 2017, Volume: 91, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Disease Progression; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Odds Ratio; Ramipril; Renin-Angiotensin System; Risk Factors; Telmisartan; Time Factors; Treatment Outcome	2017
[ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events]. Revue medicale de Liege, 2008, Volume: 63, Issue:4 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Complications; Drug Therapy, Combination; Humans; Ramipril; Risk Factors; Telmisartan; Treatment Outcome; Vascular Diseases	2008
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (London, England), 2008, Aug-16, Volume: 372, Issue:9638 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Creatinine; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney; Middle Aged; Proteinuria; Ramipril; Telmisartan	2008
Telmisartan to prevent recurrent stroke and cardiovascular events. The New England journal of medicine, 2008, Sep-18, Volume: 359, Issue:12 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Creatinine; Diabetes Mellitus; Female; Follow-Up Studies; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Potassium; Secondary Prevention; Stroke; Telmisartan; Treatment Failure	2008
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet (London, England), 2008, Sep-27, Volume: 372, Issue:9644 Topics: Aged; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cough; Female; Follow-Up Studies; Humans; Hypotension; Kaplan-Meier Estimate; Male; Risk Reduction Behavior; Single-Blind Method; Telmisartan; Therapeutic Equivalency	2008
[Remodelling of peripheral vessels in cardiovascular diseases: pathogenesis and treatment with telmisartan]. Meditsina truda i promyshlennaia ekologiia, 2008, Issue:11 Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Cardiovascular Diseases; Endothelin-1; Endothelium, Vascular; Humans; Male; Middle Aged; Nitric Oxide; Peripheral Vascular Diseases; Telmisartan; Vibration	2008
Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk. Preventive cardiology, 2009,Winter, Volume: 12, Issue:1 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Global Health; Humans; Incidence; Male; Ramipril; Risk Factors; Telmisartan; Treatment Outcome	2009
The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics. Clinical research in cardiology : official journal of the German Cardiac Society, 2009, Volume: 98, Issue:7 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Protocols; Double-Blind Method; Drug Therapy, Combination; Female; Heart Ventricles; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Quality Control; Ramipril; Reproducibility of Results; Retrospective Studies; Stroke Volume; Telmisartan; Treatment Outcome; Ventricular Dysfunction, Left	2009
Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Circulation, 2009, Oct-06, Volume: 120, Issue:14 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diastole; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; Electrocardiography; Female; Humans; Hypertrophy, Left Ventricular; Male; Odds Ratio; Placebos; Prevalence; Proportional Hazards Models; Ramipril; Regression Analysis; Systole; Telmisartan	2009
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoler Circulation, 2010, Mar-30, Volume: 121, Issue:12 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Mortality; Predictive Value of Tests; Ramipril; Telmisartan; Treatment Outcome	2010
The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics. Journal of human hypertension, 2011, Volume: 25, Issue:4 Topics: Aged; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Chi-Square Distribution; China; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Research Design; Risk Assessment; Risk Factors; Telmisartan; Time Factors; Treatment Outcome	2011
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. The Lancet. Neurology, 2011, Volume: 10, Issue:1 Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cognition Disorders; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mental Status Schedule; Neuropsychological Tests; Odds Ratio; Ramipril; Renin-Angiotensin System; Telmisartan; Treatment Outcome	2011
In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events. PloS one, 2010, Dec-21, Volume: 5, Issue:12 Topics: Angiotensin-Converting Enzyme Inhibitors; Asia; Benzimidazoles; Benzoates; Body Mass Index; Cardiovascular Diseases; Double-Blind Method; Ethnicity; Humans; Patient Compliance; Placebos; Ramipril; Risk; Telmisartan; Treatment Outcome	2010
Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TALENT study. Journal of hypertension, 2011, Volume: 29, Issue:3 Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Nifedipine; Prospective Studies; Risk; Telmisartan	2011
Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study. Diabetes care, 2011, Volume: 34, Issue:9 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus; Fasting; Female; Glucose Intolerance; Humans; Male; Middle Aged; Telmisartan	2011
Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients. Hypertension research : official journal of the Japanese Society of Hypertension, 2011, Volume: 34, Issue:11 Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Carotid Intima-Media Thickness; Female; Follow-Up Studies; Heart Ventricles; Humans; Hypertension; Hypertrophy, Left Ventricular; Japan; Losartan; Male; Middle Aged; Prospective Studies; Risk Factors; Severity of Illness Index; Single-Blind Method; Telmisartan; Treatment Outcome	2011
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation, 2011, Oct-18, Volume: 124, Issue:16 Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Guidelines as Topic; Humans; Incidence; Kidney Diseases; Middle Aged; Ramipril; Risk; Stroke; Telmisartan	2011
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). Journal of the American College of Cardiology, 2012, Jan-03, Volume: 59, Issue:1 Topics: Aged; Benzimidazoles; Benzoates; Blood Pressure Determination; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Hypotension; Kaplan-Meier Estimate; Male; Middle Aged; Patient Safety; Ramipril; Reference Values; Risk Assessment; Survival Rate; Telmisartan; Treatment Outcome	2012
Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Apr-01, Volume: 12, Issue:2 Topics: Aged; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; China; Diuretics; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Prospective Studies; Risk Factors; Telmisartan; Time Factors; Treatment Outcome	2012
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoleran Journal of hypertension, 2012, Volume: 30, Issue:5 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anthropometry; Atrial Fibrillation; Benzimidazoles; Benzoates; Body Mass Index; Cardiovascular Diseases; Diabetes Complications; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Male; Middle Aged; Placebos; Ramipril; Risk; Risk Factors; Stroke; Telmisartan; Vitamin K	2012
[Critically appraised article]. Revista medica de Chile, 2012, Volume: 140, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Middle Aged; Multicenter Studies as Topic; Proteinuria; Ramipril; Telmisartan	2012
Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures. Clinical journal of the American Society of Nephrology : CJASN, 2013, Volume: 8, Issue:2 Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Fractures, Bone; Glomerular Filtration Rate; Hip Fractures; Humans; Pelvic Bones; Prospective Studies; Ramipril; Risk Factors; Telmisartan; Time Factors	2013
Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries. Circulation, 2012, Dec-04, Volume: 126, Issue:23 Topics: Aged; Benzimidazoles; Benzoates; Cardiovascular Agents; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; Diet; Double-Blind Method; Female; Follow-Up Studies; Humans; Internationality; Male; Middle Aged; Prospective Studies; Risk Factors; Risk Reduction Behavior; Secondary Prevention; Surveys and Questionnaires; Telmisartan	2012
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmi American heart journal, 2004, Volume: 148, Issue:1 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Humans; Middle Aged; Patient Selection; Ramipril; Randomized Controlled Trials as Topic; Research Design; Telmisartan	2004
The ONTARGET/TRANSCEND Trial Programme: baseline data. Acta diabetologica, 2005, Volume: 42 Suppl 1 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Female; Humans; Hypertension; Male; Prospective Studies; Ramipril; Telmisartan	2005
Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme. The Journal of international medical research, 2005, Volume: 33 Suppl 1 Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; Middle Aged; Natriuretic Peptide, Brain; Patient Selection; Ramipril; Research Design; Telmisartan; Time Factors	2005
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telm American heart journal, 2007, Volume: 154, Issue:1 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Erectile Dysfunction; Global Health; Humans; Male; Middle Aged; Multivariate Analysis; Patient Satisfaction; Prospective Studies; Ramipril; Risk Factors; Telmisartan	2007
Arterial stiffness and pharmacological interventions--the TRanscend arterial stiffNess Substudy (TRANS study). Vascular health and risk management, 2007, Volume: 3, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arteries; Benzimidazoles; Benzoates; Blood Flow Velocity; Blood Pressure; Cardiovascular Diseases; Clinical Chemistry Tests; Double-Blind Method; Elasticity; Female; Humans; Male; Middle Aged; Telmisartan; Time Factors; Treatment Outcome	2007
Telmisartan, ramipril, or both in patients at high risk for vascular events. The New England journal of medicine, 2008, Apr-10, Volume: 358, Issue:15 Topics: Aged; Angioedema; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Creatinine; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Ramipril; Risk; Telmisartan	2008

Other Studies

57 other study(ies) available for telmisartan and Cardiovascular Diseases

Article	Year
Effects of ACE inhibitors and angiotensin receptor blockers: protocol for a UK cohort study using routinely collected electronic health records with validation against the ONTARGET trial. BMJ open, 2022, 03-08, Volume: 12, Issue:3 Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Drug Therapy, Combination; Electronic Health Records; Ethnicity; Humans; Minority Groups; Ramipril; Telmisartan; United Kingdom	2022
The Impact of Telmisartan on Cardiometabolic Risk Factors in Hypertensive Male Siblings of Women With Polycystic Ovary Syndrome. Journal of clinical pharmacology, 2021, Volume: 61, Issue:9 Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Weights and Measures; C-Reactive Protein; Cardiometabolic Risk Factors; Cardiovascular Diseases; Female; Humans; Hypertension; Insulin Resistance; Lipids; Male; Middle Aged; Polycystic Ovary Syndrome; Siblings; Telmisartan; Testosterone	2021
Use of Health Care Databases to Support Supplemental Indications of Approved Medications. JAMA internal medicine, 2018, 01-01, Volume: 178, Issue:1 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Delivery of Health Care; Drug Approval; Drug Prescriptions; Follow-Up Studies; Humans; Ramipril; Retrospective Studies; Telmisartan; United States	2018
Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats. Obesity (Silver Spring, Md.), 2013, Volume: 21, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Obesity Agents; Antihypertensive Agents; Appetite; Appetite Depressants; Benzimidazoles; Benzoates; Blood Pressure; Bridged Bicyclo Compounds, Heterocyclic; Cardiovascular Diseases; Dose-Response Relationship, Drug; Energy Intake; Feeding Behavior; Heart Rate; Male; Metoprolol; Obesity; Rats, Sprague-Dawley; Sympathomimetics; Telmisartan	2013
Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality. Hypertension (Dallas, Tex. : 1979), 2014, Volume: 63, Issue:5 Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Proportional Hazards Models; Registries; Retrospective Studies; Survival Rate; Taiwan; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan	2014
Angiotensin receptor blockers - advantages of the new sartans. The Journal of the Association of Physicians of India, 2013, Volume: 61, Issue:7 Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Hypertension; Imidazoles; Olmesartan Medoxomil; Oxadiazoles; Telmisartan; Tetrazoles; Treatment Outcome	2013
Are the effects of telmisartan more marked in hypertensive patients? Journal of hypertension, 2014, Volume: 32, Issue:6 Topics: Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cardiovascular System; Female; Humans; Hypertension; Male; Telmisartan	2014
Recent clinical trials. Journal of the American Society of Hypertension : JASH, 2014, Volume: 8, Issue:10 Topics: Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Randomized Controlled Trials as Topic; Telmisartan	2014
Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. Hypertension (Dallas, Tex. : 1979), 2015, Volume: 65, Issue:3 Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Cognition Disorders; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Incidence; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Ramipril; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Telmisartan	2015
Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study. HIV clinical trials, 2015, Volume: 16, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Anti-HIV Agents; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; CD4-Positive T-Lymphocytes; Dideoxynucleosides; Female; HIV Infections; Humans; Male; Middle Aged; Pilot Projects; Risk Factors; Telmisartan	2015
ONTARGET: questions asked, questions answered. Journal of clinical hypertension (Greenwich, Conn.), 2008, Volume: 10, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypertension; Multicenter Studies as Topic; Ramipril; Randomized Controlled Trials as Topic; Telmisartan; Treatment Outcome	2008
[What is better here: ACE inhibitor or AT1 blocker?]. MMW Fortschritte der Medizin, 2008, Apr-17, Volume: 150, Issue:16 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Ramipril; Randomized Controlled Trials as Topic; Telmisartan	2008
A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction. Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5 Suppl 1 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Body Size; Cardiovascular Diseases; Humans; Life Style; Metabolic Syndrome; Obesity; Ramipril; Renin-Angiotensin System; Risk Assessment; Risk Factors; Telmisartan	2008
[Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study]. Praxis, 2008, May-14, Volume: 97, Issue:10 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Multicenter Studies as Topic; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan	2008
Telmisartan, ramipril, or both in patients at high risk of vascular events. The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus; Drug Therapy, Combination; Humans; Ramipril; Telmisartan	2008
Telmisartan, ramipril, or both in patients at high risk of vascular events. The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4 Topics: Angioedema; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypotension; Ramipril; Telmisartan	2008
[No advantage of the combination of ACE-inhibition and angiotensin receptor blockade in patients with high cardiovascular risk]. Nederlands tijdschrift voor geneeskunde, 2008, Jun-14, Volume: 152, Issue:24 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Ramipril; Telmisartan; Treatment Outcome	2008
Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events? Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5, Issue:9 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Disease Progression; Drug Therapy, Combination; Humans; Ramipril; Randomized Controlled Trials as Topic; Research Design; Telmisartan; Treatment Outcome	2008
[ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ]. Der Internist, 2008, Volume: 49, Issue:9 Topics: Aged; Angioedema; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypotension; Ramipril; Risk Assessment; Risk Factors; Telmisartan	2008
The power to TRANSCEND. Lancet (London, England), 2008, Sep-27, Volume: 372, Issue:9644 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Middle Aged; Telmisartan; Therapeutic Equivalency	2008
[ONTARGET, PROFESS, TRANSCEND large scale studies. AT1 blockers: evidence based advantage, but less than expected]. MMW Fortschritte der Medizin, 2008, Sep-18, Volume: 150, Issue:38 Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Evidence-Based Medicine; Follow-Up Studies; Humans; Multicenter Studies as Topic; Ramipril; Randomized Controlled Trials as Topic; Telmisartan	2008
ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET. Therapeutic advances in cardiovascular disease, 2008, Volume: 2, Issue:4 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Kidney Diseases; Ramipril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Telmisartan	2008
Telmisartan for prevention of cardiovascular events. The New England journal of medicine, 2009, Jan-15, Volume: 360, Issue:3 Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Diabetes Complications; Humans; Hypertension; Secondary Prevention; Stroke; Telmisartan	2009
Telmisartan for prevention of cardiovascular events. The New England journal of medicine, 2009, Jan-15, Volume: 360, Issue:3 Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cerebral Hemorrhage; Humans; Hypertension; Secondary Prevention; Stroke; Telmisartan	2009
Telmisartan for prevention of cardiovascular events. The New England journal of medicine, 2009, Jan-15, Volume: 360, Issue:3 Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Humans; Hypertension; Secondary Prevention; Stroke; Telmisartan	2009
Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme. Diabetes research and clinical practice, 2009, Volume: 83, Issue:3 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Glucose; Cardiovascular Diseases; Cognition; Cognition Disorders; Cross-Sectional Studies; Depression; Diabetes Mellitus; Diabetic Angiopathies; Drug Therapy, Combination; Female; Glucose Intolerance; Humans; Male; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Telmisartan	2009
ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading? Blood pressure, 2009, Volume: 18, Issue:1-2 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Comorbidity; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; Ramipril; Renal Insufficiency; Risk; Stroke; Telmisartan; Treatment Outcome	2009
Telmisartan in high-risk patients intolerant of ACE inhibitors. Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662 Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Telmisartan	2009
Telmisartan in high-risk patients intolerant of ACE inhibitors. Lancet (London, England), 2009, Feb-07, Volume: 373, Issue:9662 Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diuretics; Humans; Randomized Controlled Trials as Topic; Telmisartan	2009
[The ONTARGET trial]. Giornale italiano di cardiologia (2006), 2009, Volume: 10, Issue:2 Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Research Design; Risk Factors; Telmisartan; Treatment Outcome	2009
Focus on the ONTARGET results. Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2009, Volume: 27, Issue:2 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Female; Humans; Male; Ramipril; Renin-Angiotensin System; Telmisartan	2009
Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection. Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2009, Volume: 27, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Hypertension; Ramipril; Renin-Angiotensin System; Risk Factors; Telmisartan	2009
Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor. Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2009, Volume: 27, Issue:5 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Ramipril; Retrospective Studies; Risk Factors; Telmisartan	2009
Cardiovascular protection: a breakthrough for high-risk patients? Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2009, Volume: 27, Issue:5 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Renin-Angiotensin System; Risk Factors; Telmisartan	2009
Proteinuria: Is the ONTARGET renal substudy actually off target? Nature reviews. Nephrology, 2009, Volume: 5, Issue:8 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Creatinine; Diabetes Mellitus; Disease Progression; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Kidney; Multicenter Studies as Topic; Proteinuria; Ramipril; Randomized Controlled Trials as Topic; Telmisartan	2009
[Erectile dysfunction as a harbinger of cardiovascular events. Long-term vascular protection with telmisartan]. MMW Fortschritte der Medizin, 2009, Aug-20, Volume: 151, Issue:34-35 Topics: Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Impotence, Vasculogenic; Male; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan	2009
[Positive added effect of telmisartan. New therapy alternative for a large collection of cardiovascular risk patients]. MMW Fortschritte der Medizin, 2010, Feb-25, Volume: 152, Issue:8 Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan	2010
Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension. Chronobiology international, 2010, Volume: 27, Issue:3 Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Enalapril; Female; Half-Life; Humans; Hypertension; Hypotension; Male; Middle Aged; Receptors, Angiotensin; Renin-Angiotensin System; Risk; Telmisartan	2010
Where does the evidence lead us for the proper use of angiotensin II inhibitors in the management of cardiovascular disease? Cardiology, 2010, Volume: 117, Issue:3 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cardiovascular System; Humans; Ramipril; Renin-Angiotensin System; Telmisartan	2010
Telmisartan in high-risk cardiovascular patients. No need to change standard practice. Prescrire international, 2011, Volume: 20, Issue:117 Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Ramipril; Risk Factors; Telmisartan	2011
New clinical concepts after the ONTARGET trial. Expert review of cardiovascular therapy, 2011, Volume: 9, Issue:6 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Ramipril; Telmisartan	2011
Antihypertensive and metabolic effects of telmisartan in hypertensive HIV-positive patients. Antiviral therapy, 2011, Volume: 16, Issue:5 Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Cystatin C; Endothelin-1; HIV Seropositivity; Humans; Hypertension; Insulin Resistance; Interleukin-18; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; PPAR gamma; Risk Factors; Telmisartan; Triglycerides	2011
The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study. Journal of medical economics, 2011, Volume: 14, Issue:6 Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cost of Illness; Diabetes Complications; Health Services; Heart Failure; Humans; Multicenter Studies as Topic; Myocardial Infarction; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Telmisartan	2011
Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats. Pharmacological reports : PR, 2011, Volume: 63, Issue:4 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Streptozocin; Telmisartan	2011
Is a blood pressure target of <130/80 mm Hg still appropriate for high-risk patients? Circulation, 2011, Oct-18, Volume: 124, Issue:16 Topics: Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Guidelines as Topic; Humans; Kidney Diseases; Ramipril; Telmisartan	2011
Prediction and prevention of atrial fibrillation in patients with high blood pressure or history of hypertension. Journal of hypertension, 2012, Volume: 30, Issue:5 Topics: Atrial Fibrillation; Benzimidazoles; Benzoates; Cardiovascular Diseases; Female; Humans; Male; Ramipril; Telmisartan	2012
[Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?]. MMW Fortschritte der Medizin, 2003, Dec-18, Volume: 145, Issue:51-52 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Complications; Drug Therapy, Combination; Humans; Myocardial Infarction; Placebos; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan; Time Factors	2003
Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes care, 2004, Volume: 27, Issue:4 Topics: Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Hypertension; Insulin Resistance; Male; Middle Aged; Telmisartan	2004
Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Medical hypotheses, 2005, Volume: 64, Issue:3 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; PPAR gamma; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan	2005
Introduction. Acta diabetologica, 2005, Volume: 42 Suppl 1 Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypertension; Hypoglycemic Agents; Obesity; Telmisartan	2005
[Revised blood pressure goals and no elevated glucose readings in between]. MMW Fortschritte der Medizin, 2005, Dec-15, Volume: 147, Issue:51-52 Topics: Acarbose; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Glucose Self-Monitoring; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperglycemia; Hypertension; Hypoglycemic Agents; Postprandial Period; Risk Factors; Telmisartan	2005
[In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension]. MMW Fortschritte der Medizin, 2006, Jun-29, Volume: 148, Issue:26 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypertension; Metabolic Syndrome; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan; Time Factors	2006
The effects of simultaneous administration of dietary conjugated linoleic acid and telmisartan on cardiovascular risks in rats. Lipids, 2007, Volume: 42, Issue:9 Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cytokines; Dietary Supplements; Fructose; Insulin; Intra-Abdominal Fat; Linoleic Acids, Conjugated; Lipids; Male; Rats; Rats, Sprague-Dawley; Risk Factors; Telmisartan; Time Factors	2007
[Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection]. MMW Fortschritte der Medizin, 2007, Dec-06, Volume: 149, Issue:49-50 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Telmisartan	2007
ACE inhibitors in cardiovascular disease--unbeatable? The New England journal of medicine, 2008, Apr-10, Volume: 358, Issue:15 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Ramipril; Research Design; Telmisartan; Tetrazoles; Valine; Valsartan	2008
Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats. Molecular and cellular biochemistry, 2008, Volume: 314, Issue:1-2 Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Experimental; Drug Evaluation, Preclinical; Female; Heart Rate; Hypertrophy, Left Ventricular; Models, Biological; Rats; Rats, Wistar; Streptozocin; Telmisartan	2008
Telmisartan as a metabolic sartan for targeting vascular failure. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:8 Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Cholesterol; Glucose; Humans; Hypertriglyceridemia; Metabolic Syndrome; PPAR gamma; Risk Factors; Telmisartan	2008